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Objectives: Vardenaﬁl, a clinically approved cGMP-dependent phosphodiesterase
type 5 inhibitor (PDE5i), is able to increase defective F508del-CFTR chloride
transport across the mouse nasal mucosa. This work aimed at studying the effect
of vardenaﬁl to rescue CFTR function and localization at the gastrointestinal (GI)
tract, affected in 85% of CF patients.
Methods: CFTR function was assessed by quantifying potential difference across
the rectal mucosa. Sodium hyperabsorption (40.2±4.0mV vs 20±1.8mV; p< 0.001;
mean±SEM) and reduced chloride transport (−4.2±0.5mV vs −9.4±0.9mV;
p = 0.002) were typically found in F508del-CFTR (CF) compared to wild-type
(WT) mice. Vardenaﬁl, applied as a single intraperitoneal dose (0.14mg/kg)
completely restored chloride transport (−9.3±1.2mV) in CF. Immunohistostaining
studies showed reduced CFTR expression at cell membrane in CF mouse colon
preparations: in untreated conditions, the ratio of CFTR-speciﬁc ﬂuorescence (RF)
of the cell membrane and that of the rest of the cell was lower in CF (1.4±0.1) than
in WT (1.9±0.1; p< 0.001). The RF was increased in vardenaﬁl-treated (2.2±0.1)
compared to untreated CF colon tissues (p< 0.0001).
Conclusion: Our ﬁndings pointed out the intestinal mucosa as an additional valuable
target tissue to study CFTR function and localization and to evaluate efﬁcacy of
therapeutic strategies in CF. Vardenaﬁl also restores ion transport abnormalities
across the GI epithelium acting as a corrector of the cell mislocalization of F508del-
CFTR.
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Objectives: CFTR modulators VX770 (ivacaftor), VX809 and PTC124 have been
investigated in clinical phase trials. Prediction of clinical effects at a preclinical
stage is complicated by the lack of optimal models. Aim of this study was to
evaluate the preclinical ex vivo effect of CFTR modulators on human rectal CFTR
function, to provide a basis for long-term correlations with clinical in vivo effects.
Methods: Rectal suction biopsies (n = 256) from 11 PI-CF patients (6 F508del-
homozygous, 5 with nonsense-mutation), 8 PS-CF patients (Class IV-V mutation)
and 13 healthy controls were freshly procured for Intestinal Current Measurement
(ICM). Transepithelial short-circuit current was measured according to the ECFS
ICM SOP, before and after ex vivo incubation for 16 hours (37ºC, 95% O2, 5%
CO2) with VX809 (10−30mM), VX770 (10−30mM), PTC124 (10mM), Gentamicin
400mg/ml, combinations or DMSO 0.1%.
Conclusion: F508del-CFTR function was partially corrected by ex vivo treatment
with VX809 to a level up to 25% of non-CF control (DMSO). PTC124 enhanced
CFTR function in CF rectal biopsies with at least one nonsense-mutation to 14.4%
of non-CF control, whereas gentamicin showed no effect. In PS-CF with class
IV-V mutations, VX770 normalised CFTR function from residual to levels of non-
CF. These data indicate the high potential of ICM for preclinical CFTR modulator
testing in native ex vivo human tissues. The technique might be helpful for mutation-
speciﬁc individual prediction of clinical in vivo drug effects and early identiﬁcation
of responders and non-responders of CFTR modulating therapies.
This study was supported by Mukoviszidose e.V., Germany.
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The F508del-CFTR mutation affects folding and trafﬁcking of CFTR, resulting in
defective gating and little to no CFTR activity at the epithelial surface. VX-661, an
investigational CFTR corrector, increases F508del-CFTR protein activity in vitro,
both alone and in combination with ivacaftor, and appears to enhance F508del-
CFTR trafﬁcking to the cell surface. An ongoing study, VX-661-101 (Study 101),
evaluates the safety and efﬁcacy of VX-661 alone and in combination with ivacaftor
in patients (pts) with cystic ﬁbrosis (CF) homozygous for the F508del-CFTR
mutation. This interim analysis evaluates the safety of escalating VX-661 doses.
This is a Phase 2, randomized, double-blind, placebo-controlled, 3-part study. In
Part A, approximately 120 adult (18 yrs) pts homozygous for the F508del-CFTR
mutation and with FEV1 40 to 90% of predicted, will be randomized into dosing
groups of VX-661 alone (10, 30, 100, or 150mg qd) or in combination with
ivacaftor (150mg q12 h) for 28 days. The primary measures are safety and change
in sweat chloride (baseline–Day 28). Secondary measures include changes in FEV1
and in CFQ-R (baseline–Day 28).
Approximately 130 pts are expected to enroll into the 10, 30, 100, or 150mg
dosing groups of VX-661 alone or in combination with ivacaftor, and enrollment is
expected to be completed by early 2013. Interim analyses results will be reported.
Preliminary data, including safety, changes in sweat chloride, FEV1 % predicted
and CFQ-R are anticipated to be available at time of presentation.
The safety and efﬁcacy proﬁle of VX-661, with and without ivacaftor, in adult CF
pts homozygous for the F508del-CFTR mutation will be reported.
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Lumacaftor enhanced F508del-CFTR protein trafﬁcking in vitro, and addition
of ivacaftor to lumacaftor increased chloride transport. The safety/efﬁcacy of
lumacaftor alone and in combination with ivacaftor in CF patients (pts) with the
F508del-CFTR mutation is being evaluated in VX-809 Study 102. This interim
analysis evaluates the safety/efﬁcacy of escalating lumacaftor doses.
This is a Phase 2, randomized, placebo-controlled study. In Cohorts 2 (n = 109)
and 3 (n = 15), pts received either lumacaftor (Cohort 2: 200, 400 or 600mg qd;
Cohort 3: 400mg q12 h) for Days 0−28 (Period 1) plus lumacaftor (continued same
dose) combined with ivacaftor 250mg q12 h for Days 28−56 (Period 2), or placebo
(Periods 1 and 2). Safety, FEV1, and sweat chloride were examined.
In Cohort 2, most adverse events were mild/moderate and comparable between
treatment groups. A subset of pts reported generally mild and self-limited episodes
of dyspnea/chest tightness coincident with initiation of 600mg qd lumacaftor. Lung
function was generally stable in Period 1. Signiﬁcant increases in FEV1 were
observed during Period 2 in all dose groups vs placebo. The greatest increase in %
predicted FEV1 was observed in the 600mg lumacaftor plus ivacaftor homozygous
group vs placebo (8.6% absolute, 12.8% relative) (p< 0.001). In this same group,
sweat chloride was reduced with lumacaftor alone (Period 1) (−6.41mmol/L) and
with ivacaftor (Period 2) (additional −3.66mmol/L) vs placebo.
In this interim analysis of pts with the F508del-CFTR mutation, lumacaftor alone
or in combination with ivacaftor was well tolerated, and the combination had lung
function improvement in Cohort 2. Cohort 3 will be presented.
